Facebook Twitter
Wsj India


Dow /quotes/zigman/627449/realtime 16,413 -160 0.96% Nasdaq /quotes/zigman/12633936/realtime 4,128 -110 2.59% /quotes/zigman/3870025/realtime 1,865 -24 1.26% SmartMoney
Feature Andrew Bary Shares of orphan drug maker Sarepta could soar if the FDA gives an early go-ahead to its drug for Duchenne muscular dystrophy. Profile Sarah Max Smead Value: Worth the Wait William Smead has a long history of patience. He's willing to wait for the stocks of companies offering in-demand products to fall in value. Feature Sandra Ward Raytheon Plays Offense as Defense Tightens The big Pentagon contractor has a hot hand in cybersecurity and sells lots of missile systems overseas.




Asia shares open higher in thin trade; US gains support Top News & Analysis Here's what will drive stocks next week CNBC
CNNMoney - 4 hours ago Bank of America reported a quarterly loss Wednesday as legal costs hit the bank's bottom line. It's another reminder that the tentacles of the financial crisis are still squeezing Wall Street. Google


There's plenty of evidence that most managers dislike their jobs. To change that, says one expert, stop trying to be someone you're not. Americans have racked up $150 billion in private student loan debt, with many graduates owing more than they can afford according to the Consumer Financial Protection Bureau. The major flaw in trying to time the market is that you not only have to make one correct call, but two: exit at the right time and get back in at the right time. What's more, you've got to do it again and again, as long as you invest. A look at a Fortune career advice column from 1956 shows just how much the working world has changed over the past half century. CNNMoney CNNMoney
BusinessWeek Bloomberg Businessweek Continue to Businessweek Sign in with Facebook Or use your Businessweek account Forgot password? Already a user? Sign in with the same account.